Crescent Biopharma, Inc. (CBIO) stock
CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 10/30
$14.37−0.39 (-2.61%)
Close on Nov 12, 2026Market cap $533.76MP/E –Yield –
Crescent Biopharma operating margin
Operating margin is operating income as a percentage of revenue.
Crescent Biopharma's operating margin for the twelve months ending Sep 30, 2026 was -1216.6%. For fiscal 2025 it was -1407.5%, against -392752.9% the year before. The highest annual figure on record is 23.8% in fiscal 2012.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1407.5% | +391345.4 |
| FY2023 | Dec 31, 2023 | -392752.9% | −329548.5 |
| FY2022 | Dec 31, 2022 | -63204.4% | −57733.7 |
| FY2021 | Dec 31, 2021 | -5470.7% | −4963.8 |
| FY2020 | Dec 31, 2020 | -506.8% | +171998.5 |
| FY2016 | Dec 31, 2016 | -172505.3% | −172441.6 |
| FY2015 | Dec 31, 2015 | -63.7% | +10.4 |
| FY2014 | Dec 31, 2014 | -74.1% | +191.5 |
| FY2013 | Dec 31, 2013 | -265.7% | −289.5 |
| FY2012 | Dec 31, 2012 | 23.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1280.3% | +97589.9 |
| Q1 FY2026 | Mar 31, 2026 | -2380.1% | +17648.7 |
| Q4 FY2025 | Dec 31, 2025 | -843.7% | +10143157.7 |
| Q2 FY2022 | Jun 30, 2022 | -17804.2% | −16451.2 |
| Q4 FY2021 | Dec 31, 2021 | -98870.2% | −89315.3 |
| Q3 FY2021 | Sep 30, 2021 | -20028.8% | −18656.1 |
| Q2 FY2021 | Jun 30, 2021 | -10144001.4% | −10143911.3 |
| Q1 FY2021 | Mar 31, 2021 | -1353.0% | – |
| Q4 FY2020 | Dec 31, 2020 | -9554.9% | – |
| Q3 FY2020 | Sep 30, 2020 | -1372.7% | – |
| Q1 FY2020 | Mar 31, 2020 | -90.1% | – |
See a number that looks wrong?